Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2021 Financial Results on August 9th
02 8월 2021 - 9:00PM
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company primarily
focused on developing FT218, an investigational, once-nightly
formulation of sodium oxybate designed to treat excessive daytime
sleepiness (EDS) and cataplexy in adults with narcolepsy, announced
today that it will host a conference call and live webcast at 8:30
a.m. ET on Monday, August 9, 2021, to provide a corporate update
and discuss the Company's financial results for the second quarter
ended June 30, 2021.
To access the conference call, investors are invited to dial
(844) 388-0559 (U.S. and Canada) or (216) 562-0393 (International).
The conference ID number is 4560878. A live audio webcast can be
accessed by visiting the investor relations section of the
Company’s website, www.avadel.com. A replay of the webcast will be
archived on Avadel’s website for 90 days following the event.
About Avadel Pharmaceuticals plcAvadel
Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company
primarily focused on the development and U.S. Food and Drug
Administration (FDA) approval of FT218, an investigational,
once-nightly, extended-release formulation of sodium oxybate
designed to treat excessive daytime sleepiness and cataplexy in
adults with narcolepsy. For more information, please visit
www.avadel.com.
Investor Contact:Courtney TurianoStern Investor
Relations, Inc.Courtney.Turiano@sternir.com (212) 698-8687
Media Contact:Nicole Raisch GoelzReal
Chemistryngoelz@realchemistry.com (408) 568-4292
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024